HUTCHMED (China) Limited
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- HUTCHMED (China) Limited is an innovative commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted therapeutics and immunotherapies primarily for cancer and immunological diseases. The company’s main products include oncology and immunology drugs such as FRUZAQLA® (fruquintinib), a targeted therapy for colorectal cancer marketed in over 30 countries through its partner Takeda, and savolitinib (ORPATHYS®), a selective oral MET inhibitor for non-small cell lung cancer, developed in collaboration with AstraZeneca. HUTCHMED’s product portfolio also encompasses antibody-targeted therapy conjugates (ATTCs), combining antibodies with targeted therapeutics, with new clinical candidates expected to enter trials in late 2025. The company operates through its Oncology/Immunology segment, focused on drug discovery and commercialization, alongside other ventures including the manufacture, sale, and distribution of prescription drugs and healthcare products primarily in China. HUTCHMED was founded in 2000 and is headquartered in Hong Kong. It conducts global clinical development and commercialization activities, with significant operations in China, the US, Europe, and Japan. The company maintains partnerships for commercial and clinical development, including licensing arrangements with multinational pharmaceutical companies such as Takeda and AstraZeneca. In recent strategic developments, HUTCHMED completed a $608 million divestment of a 45% equity interest in its non-core joint venture Shanghai Hutchison Pharmaceuticals (SHPL) to focus on its core business of innovative drug development, specifically its antibody-targeted therapy conjugate platform. This divestment occurred in early 2025 and is intended to fund advancement in its core oncology pipeline. HUTCHMED also reported significant sales growth in oncology products in 2024, with FRUZAQLA® achieving over $290 million in ex-China sales, and expanded its commercial reach globally. The company launched new clinical studies and expanded indications for its key therapies, including positive phase II results for savolitinib in combination with osimertinib for lung cancer. HUTCHMED continues to enhance its pipeline with new ATTC platform candidates and is preparing for additional product launches, including sovleplenib for idiopathic thrombocytopenic purpura in China. Overall, HUTCHMED leverages in-house research and a broad clinical pipeline in oncology and immunology with robust commercialization efforts and strategic global partnerships to drive growth and innovation in biopharmaceuticals. The company has around 1,800 employees and remains committed to expanding its global footprint while focusing on advanced therapeutic modalities and targeted therapies. This description integrates HUTCHMED’s main products, geographic reach, founding, and headquarters details, with the latest changes including its 2025 divestment of SHPL, pipeline advancements, drug launches, and strong sales performance in oncology therapeutics.
Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts
AI Solution Providers Shift From AI Features to AI-Enabled Execution
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
HUTCHMED to Announce 2026 Half-Year Financial Results
Buy These 3 HCM Software Solution Stocks to Tap Short-Term Potential
Syndio Acquires Embrace.ai
isolved Introduces Autonomous AI Agents Built to Own HR Outcomes — Brings Unified HCM Platform to Anthropic's Claude Connectors Directory
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
isolved Honors Top-Performing Partners at Annual Connect for Partners Event
isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees
Paychex Recognized as a Top WorkTech Company by TIME
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
U.S. Office of Personnel Management Selects Oracle to Power Federal Workforce Modernization
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms